Bank Of America Corp Impel Pharmaceuticals Inc Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.96 - $4.1 $29 - $127	-31 Reduced 93.94%	2 $0
Q4 2022 Feb 10, 2023	SELL	$2.59 - $4.0 $453 - $700	-175 Reduced 84.13%	33 $0
Q3 2022 Nov 14, 2022	SELL	$5.78 - $9.32 $1,820 - $2,935	-315 Reduced 60.23%	208 $1,000
Q2 2022 Aug 12, 2022	SELL	$5.83 - $10.12 $83,864 - $145,576	-14,385 Reduced 96.49%	523 $4,000
Q1 2022 May 16, 2022	SELL	$5.86 - $9.85 $12,587 - $21,157	-2,148 Reduced 12.59%	14,908 $95,000
Q4 2021 Feb 08, 2022	BUY	$8.33 - $12.14 $95,670 - $139,427	11,485 Added 206.16%	17,056 $148,000
Q3 2021 Nov 15, 2021	BUY	$8.38 - $26.13 $43,743 - $136,398	5,220 Added 1487.18%	5,571 $68,000
Q2 2021 Sep 13, 2021	BUY	$7.33 - $15.2 $2,572 - $5,335	351 New	351 $3,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.